BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36685670)

  • 1. A Novel Nomogram Combined the Aggregate Index of Systemic Inflammation and PIRADS Score to Predict the Risk of Clinically Significant Prostate Cancer.
    Xie W; Xu Z; Qiu Y; Ye W; Zhang Z; Wang C; Zang J
    Biomed Res Int; 2023; 2023():9936087. PubMed ID: 36685670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a nomogram combining multiparametric magnetic resonance imaging and PSA-related parameters to enhance the detection of clinically significant cancer across different region.
    Zhou Z; Liang Z; Zuo Y; Zhou Y; Yan W; Wu X; Ji Z; Li H; Hu M; Ma L
    Prostate; 2022 Apr; 82(5):556-565. PubMed ID: 35098557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
    Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
    Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel nomogram combined PIRADS v2 and neutrophil-to-lymphocyte ratio to predict the risk of clinically significant prostate cancer in men with PSA < 10 ng/ml at first biopsy.
    Sun J; Zhang Z; OuYang J
    Urol Oncol; 2020 May; 38(5):401-409. PubMed ID: 31870724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential of a nomogram combined PI-RADS v2.1 and contrast-enhanced ultrasound (CEUS) to reduce unnecessary biopsies in prostate cancer diagnostics.
    Liu Y; Wang S; Xiang LH; Xu G; Dong L; Sun Y; Ye B; Zhang Y; Xu H
    Br J Radiol; 2022 Sep; 95(1138):20220209. PubMed ID: 35877385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and external validation of a novel nomogram to predict prostate cancer in biopsy-naïve patients with PSA <10 ng/ml and PI-RADS v2.1 = 3 lesions.
    Hu C; Sun J; Xu Z; Zhang Z; Zhou Q; Xu J; Chen H; Wang C; Ouyang J
    Cancer Med; 2023 Feb; 12(3):2560-2571. PubMed ID: 35920264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel clinically significant prostate cancer prediction system with multiparametric MRI and PSA: P.Z.A. score.
    Chen Z; Zhang J; Jin D; Wei X; Qiu F; Wang X; Zhao X; Pu J; Hou J; Huang Y; Huang C
    BMC Cancer; 2023 Nov; 23(1):1138. PubMed ID: 37996859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment and validation of serum lipid-based nomogram for predicting the risk of prostate cancer.
    Feng F; Zhong YX; Chen Y; Lin FX; Huang JH; Mai Y; Zhao PP; Wei W; Zhu HC; Xu ZP
    BMC Urol; 2023 Jul; 23(1):120. PubMed ID: 37452418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploration of the diagnostic capacity of PSAMR combined with PI-RADS scoring for clinically significant prostate cancer and establishment and validation of the Nomogram prediction model.
    Li D; Zhang L; Xu Y; Wu X; Hua S; Jiang Y; Huang Q; Gao Y
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11309-11317. PubMed ID: 37365430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modified Predictive Model and Nomogram by Incorporating Prebiopsy Biparametric Magnetic Resonance Imaging With Clinical Indicators for Prostate Biopsy Decision Making.
    Pan JF; Su R; Cao JZ; Zhao ZY; Ren DW; Ye SZ; Huang RD; Tao ZL; Yu CL; Jiang JH; Ma Q
    Front Oncol; 2021; 11():740868. PubMed ID: 34589437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel Prediction Tool Based on Multiparametric Magnetic Resonance Imaging to Determine the Biopsy Strategy for Clinically Significant Prostate Cancer in Patients with PSA Levels Less than 50 ng/ml.
    He BM; Shi ZK; Li HS; Lin HZ; Yang QS; Lu JP; Sun YH; Wang HF
    Ann Surg Oncol; 2020 Apr; 27(4):1284-1295. PubMed ID: 31848822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and internal validation of a nomogram predicting significant prostate cancer: Is it clinically applicable in low prevalent prostate cancer countries? A multicenter study.
    Arafa MA; Farhat KH; Khan FK; Rabah DM; Elmorshedy H; Mokhtar A; Al-Taweel W
    Prostate; 2024 Jan; 84(1):56-63. PubMed ID: 37759243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing detection of clinically significant prostate cancer through nomograms incorporating mri, clinical features, and advanced serum biomarkers in biopsy naïve men.
    Siddiqui MR; Li EV; Kumar SKSR; Busza A; Lin JS; Mahenthiran AK; Aguiar JA; Shah PV; Ansbro B; Rich JM; Moataz SAS; Keeter MK; Mai Q; Mi X; Tosoian JJ; Schaeffer EM; Patel HD; Ross AE
    Prostate Cancer Prostatic Dis; 2023 Sep; 26(3):588-595. PubMed ID: 36973367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biparametric Magnetic Resonance Imaging-Derived Nomogram to Detect Clinically Significant Prostate Cancer by Targeted Biopsy for Index Lesion.
    Kim MJ; Park SY
    J Magn Reson Imaging; 2022 Apr; 55(4):1226-1233. PubMed ID: 34296803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nomograms for predicting clinically significant prostate cancer in men with PI-RADS-3 biparametric magnetic resonance imaging.
    Liang Z; Feng T; Zhou Y; Yang Y; Sun Y; Zhou Z; Yan W; Cao F
    Am J Cancer Res; 2024; 14(1):73-85. PubMed ID: 38323293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The diagnostic effectiveness of serum sialic acid predicts both qualitative and quantitative prostate cancer in patients with prostate-specific antigen between 4 and 20 ng/mL.
    Sun J; Yan L
    Front Endocrinol (Lausanne); 2023; 14():1188944. PubMed ID: 37645415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined multiple clinical characteristics for prediction of discordance in grade and stage in prostate cancer patients undergoing systematic biopsy and radical prostatectomy.
    Liu H; Tang K; Xia D; Peng E; Wang L; Chen Z
    Pathol Res Pract; 2020 Nov; 216(11):153235. PubMed ID: 33035728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An integrated nomogram combining deep learning, Prostate Imaging-Reporting and Data System (PI-RADS) scoring, and clinical variables for identification of clinically significant prostate cancer on biparametric MRI: a retrospective multicentre study.
    Hiremath A; Shiradkar R; Fu P; Mahran A; Rastinehad AR; Tewari A; Tirumani SH; Purysko A; Ponsky L; Madabhushi A
    Lancet Digit Health; 2021 Jul; 3(7):e445-e454. PubMed ID: 34167765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New model of PIRADS and adjusted prostatespecific antigen density of peripheral zone improves the detection rate of initial prostate biopsy: a diagnostic study.
    Huang C; Cai ZQ; Qiu F; Pu JX; Xi QL; Wei XD; Wang XM; Zhao XJ; Guo LC; Hou JQ; Huang YH
    Asian J Androl; 2023; 25(1):126-131. PubMed ID: 35488668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A nomogram for prediction of prostate cancer on multi-core biopsy using age, serum prostate-specific antigen, prostate volume and digital rectal examination in Singapore.
    Lee A; Lim J; Gao X; Liu L; Chia SJ
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e348-e355. PubMed ID: 27641069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.